Figure 5 | Scientific Reports

Figure 5

From: Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer

Figure 5

Kaplan- Meier analysis of OS and RFS probabilities based on the expression levels of three candidate genes. (A,C,E) Survival curves of lung cancer patients according to the status of NEK2/DLGAP5/ECT2 expression levels. Patients with high NEK2/DLGAP5/ECT2 expression showed significantly poorer OS than those with low NEK2/DLGAP5/ECT2 expression (P = 0.009, P = 0.001; P = 0.007, respectively). (B,D,F) RFS of lung cancer patients according to the status of NEK2/DLGAP5/ECT2 expression levels. Patients with high NEK2/DLGAP5/ECT2 expression showed significantly poorer RFS than those with low NEK2/DLGAP5/ECT2 expression (P = 0.006, P = 0.003; P = 0.005, respectively).

Back to article page